Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5218MR)

This product GTTS-WQ5218MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5218MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14223MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ13384MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ15907MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8768MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ12847MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ3461MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ1374MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ1338MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-806
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW